<DOC>
	<DOCNO>NCT00713128</DOCNO>
	<brief_summary>This study determine much nausea vomit cause irinotecan-based chemotherapy patient colorectal cancer . Patients colorectal cancer schedule receive first cycle irinotecan-based chemotherapy regimen eligible . Any chemotherapy agent administer combination irinotecan must low-minimal potential cause nausea vomit . Examples acceptable regimen would irinotecan combination infusional fluorouracil leucovorin ( FOLFRI ) without bevacizumab irinotecan combination cetuximab . Patients receive prior non-irinotecan-based chemotherapy eligible providing experience vomit great mild nausea prior chemotherapy .</brief_summary>
	<brief_title>Evaluation Incidence Nausea Vomiting Patients With Colorectal Cancer Receiving Irinotecan-based Therapy</brief_title>
	<detailed_description>Irinotecan camptothecin analog exert cytotoxic effect form covalent complex topoisomerase I DNA , result inhibition DNA re-ligation , accumulation DNA double strand break apoptotic cell death ( 1 ) . Irinotecan FDA approve use front-line second-line treatment colorectal cancer . It also demonstrate activity variety non-hematologic tumor . The recently update ASCO antiemetic guideline characterize irinotecan moderate emetic risk . ( 2 ) . However , emetogenic potential agent poorly characterize publish prospective trial emesis primary-end point . In addition complete paucity information potential irinotecan induce emesis beyond first day chemotherapy , so-called delayed emesis . Best characterize follow cisplatin , delay emesis also associate number chemotherapy agent similar irinotecan appear moderately emetogenic carboplatin , cyclophosphamide doxorubicin . Antiemetic prophylaxis delay emesis follow irinotecan routinely prescribed present time . Prospectively obtain information potential irinotecan cause delay emesis would helpful guide appropriate antiemetic practice .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>Patients colorectal cancer receive irinotecan combination infusional fluorouracil leucovorin ( FOLFRI ) without bevacizumab irinotecan combination cetuximab All patient receive follow standard antiemetic regimen prior chemotherapy : Dexamethasone 8 mg PO/IV An approve dose 5HT3 receptor antagonist . Ondansetron 8mg IV 24mg PO Dolasetron 100mg IV/PO Granisetron 1 mg IV 2mg PO Use palonosetron exclude trial No routine prophylaxis delay emesis give . Patients instructed use rescue antiemetic need . Minimum age 18 year . Premenopausal patient must demonstrate negative serum urine pregnancy test prior receive chemotherapy . ECOG performance status 02 ( Appendix A ) Execution write informed consent Patients history moderatesevere nausea vomit prior chemotherapy include irinotecan base chemotherapy . Concomitant use drug potential antiemetic efficacy ( Appendix B ) 24 hour chemotherapy 120 hour study period . Chronic use ( 2 week ) benzodiazepine allow . Vomiting , retch nausea ( NCI &gt; 1 ) 24 hour precede chemotherapy Palliative surgery &lt; 2 week study entry Concurrent radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>nausea vomit colorectal cancer</keyword>
</DOC>